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The kidney plays a fundamental role in the regulation of arterial blood pressure and ﬂuid/electrolyte homeostasis. As congenital
anomalies of the kidney and urinary tract (CAKUT) constitute one of the most common human birth defects, improved
understanding of the cellular and molecular mechanisms that lead to CAKUT is critical. Accumulating evidence indicates that
aberrant signaling via receptor tyrosine kinases (RTKs) is causally linked to CAKUT. Upon activation by their ligands, RTKs
dimerize, undergo autophosphorylation on speciﬁc tyrosine residues, and interact with adaptor proteins to activate intracellular
signal transduction pathways that regulate diverse cell behaviours such as cell proliferation, survival, and movement. Here, we
review the current understanding of role of RTKs and their downstream signaling pathways in the pathogenesis of CAKUT.
1.Introduction
1.1. Brief Overview of Kidney Development. Development
of the kidney and urinary tract begins when the nephric
duct (ND) is formed from the intermediate mesoderm on
embryonic (E) day E22 in humans and E8 in mice [6].
The ND extends caudally and forms an epithelial outgrowth
called the ureteric bud(UB)(E28 inhumans; E10.5 in mice),
which invades the adjacent metanephric mesenchyme (MM)
[6]( F i g u r e1). The permanent or metanephric kidney is
formed via reciprocal inductive interactions between the
UB and the MM [7, 8]. UB outgrowth from the ND
is followed by its repetitive branching, a process called
branching morphogenesis [9, 10]. Initial generations of UB
branches will form the ureter, renal pelvis, and calyces,
whereas subsequentgenerationsofUBbrancheswill giverise
tocollectingducts.Distalureterwill translocate fromtheND
to eventually fuse with the bladder [11, 12]. Each UB tip is
capable of inducing the adjacent metanephric mesenchyme
to form nephrons (from the glomerulus through the distal
tubule) [9]. UB signals to MM by secreting wingless 9b
(Wnt9b), a soluble growth factor, which acts via canonical
β catenin to induce expression of ﬁbroblast growth factor
8 (FGF8), LIM homeobox 1 (Lhx1) and Wnt4 in the MM
[7, 8, 13–15]. In turn, Wnt4 induces MM cells to undergo
mesenchymal-to-epithelial transformation (MET) and dif-
ferentiate into nephron epithelia [13]. Six2, a homeodomain
transcription factor expressed in the MM, maintains MM
cells in undiﬀerentiated state, thereby allowing continued
UB branching and nephron formation to proceed [16].
Aberrant UB branching or nephron endowment is causally
linked to congenital anomalies of the kidney and urinary
tract (CAKUT), hypertension and eventual progression, to
chronic renal failure [7, 17, 18]. Although some forms of
CAKUT are a part of a syndrome, most cases of renal system
anomalies are sporadic and isolated to the urinary tract.
1.2. Receptor Tyrosine Kinases (RTKs). RTKs and their spe-
ciﬁc ligands are key regulators of critical cellular processes
such as proliferation, survival, diﬀerentiation, and migra-
tion [19, 20]. Mutations in RTKs and aberrant activation
of their signaling pathways have been causally linked to
numerous diseases including cancers and CAKUT. For
example, mutations rearranged during transfection (Ret)
RTK in humans cause medullary thyroid carcinoma, breast
cancer, and Hirschsprung disease [21, 22]. Humans have
58 known RTKs [23]. All RTKs have a common molecular
architecture and are composed of ligand-binding domain
in the extracellular region, a single transmembrane helix,2 Journal of Signal Transduction
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Figure 1: Schematic representation of normal development of the human kidney. (a) Invasion of the metanephric mesenchyme (MM)
by the ureteric bud (UB) induces MM cells to aggregate around the UB tip. (b) MM cell aggregates undergo mesenchymal-to-epithelial
transformation (MET) to form the renal vesicle (RV). (c) RV elongates along the proximal-distal axis to form comma-shaped and then
S-shaped nephron. Distal ends of S-shaped nephrons fuse with UB-derived collecting ducts, whereas proximal clefts form glomeruli.
Endothelial cells migrate into the proximal cleft. (d) Patterning of the S-shaped nephron and UB result in formation of mature nephron
which containsglomerular capillary tuft, podocytes, proximal tubule (PT), loop of Henle, distal tubule (DT), and collecting duct. Please see
text for details.
a cytoplasmic region that contains the tyrosine kinase
and C-terminal domains. Upon activation by their lig-
ands, RTKs dimerize and undergo autophosphorylation on
speciﬁc tyrosine residues leading to activation of intrinsic
protein tyrosine kinase activity. In turn, these docking phos-
photyrosines recruit speciﬁc intracellular adaptor proteins
[phospholipase C gamma (PLCγ), growth factor receptor-
bound protein 2 (Grb2), Src, Shc] and activate intracellular
signal transduction pathways such as phosphatidylinosi-
tol 3-kinase (PI3K)/Akt, Ras/extracellular signal-regulated
(Erk1/2) mitogen-activated protein (MAP) kinases or pro-
tein kinase C (PKC) [23, 24]. PI3Ks and MAP kinases are
families of ubiquitously expressed proteins that mediate the
eﬀectsof RTKs on cell proliferation, survival, diﬀerentiation,
migration, and cytoskeletal reorganization [19, 20, 25]. In
this review, we outline the role of RTKs and their respective
ligands in normal and abnormal metanephric kidney devel-
opment and discuss insights into the mechanisms by which
aberrant RTK signaling causes CAKUT.
1.3. Genetic Mutations in RTKs Associated with CAKUT.
Over the past decade, a number of RTKs and their respective
ligands have been implicated in the control of metanephric
kidney and urinary tract development. RTKs essential
for normal metanephric development include rearranged
during transfection (Ret), ﬁbroblast growth factor receptor
2 (FGFR2), epidermal growth factor receptor (EGFR),
hepatocyte growth factor (HGF) receptor, Met, vascular
endothelial growth factor receptor 1 (VEGFR1/Flt1), vas-
cular endothelial growth factor receptor 2 (VEGFR2/KDR),
platelet-derived growth factor receptors α and β (PDGFRα,
PDGFRβ), and insulin growth factor (IGF) receptors
(IGF1R, IGF2R) (Table 1,F i g u r e s2 and 3). In addition to
RTKswith known roles in kidneyorganogenesis, other RTKs
with no speciﬁc renal functions assigned to them to date
are also expressed in the developing kidney. For example,
ROS1, the human homolog of the transforming gene v-ros
of the avian sarcoma virus UR2, is expressed in distinctive
fashion duringkidneydevelopmentinmice.OnE11.0,ROS1
mRNA is present in the ND and the UB [46]. From E13.0
and throughout further development ROS1 is expressed
speciﬁcally in UB tips. This spatial distribution suggests a
direct role for ROS1 in inductive interactions between the
UB and metanephric mesenchyme. Genetic inactivation of
ROS1 in mice leads to aberrant regionalization and terminal
diﬀerentiation of epithelial cells in the epididymis, but does
not appear to alter histology of the developing kidney [47].
Notably, ROS1-null male mice do not reproduce. This is
presumably due to defects in sperm maturation or ability
of sperm to fertilize in vivo [47]. RTK ligands that play an
important role in kidney development include EGF, FGF7,
FGF8, FGF10, GDNF, HGF, IGF1, PDGF-B, and VEGF
(Table 2,F i g u r e3).
2.Ret
The glial-derived neurotrophic factor (GDNF)/Ret pathway
is the major inducer of UB and kidney development [48].
GDNF, a growth factor secreted by metanephric mesenchy-
mal cells, interacts with its RTK, Ret, a proto-oncogene
expressed in the ND to induce epithelial cell rearrangement
and migration leading to the formation of the primary
UB [49]. In addition, GDNF stimulates Ret signaling in
the UB tip cells to induce UB branching and nephron
formation [50].Genetic inactivation of GDNFor Retin mice
results in a failure to form a UB and perinatal death with
bilateral kidney agenesis [26, 42]. Notably, mutations in Ret
(OMIM#164762) are found in 35% of humans with various
forms ofrenal agenesis [51].Animal modelsystems provided
valuableinsightsinto thecellularandmolecularmechanismsJournal of Signal Transduction 3
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Figure 2: Schematic representation of the role of receptor tyrosine kinases (RTKs) in ureteric bud morphogenesis (UB) and kidney
development. Growth factor ligands bind simultaneously with two cognate cell surface RTK molecules and cross-link them into a dimeric
complex. This is followed by phosphorylation (P) ofcritical tyrosine (Y) residues ofthe intracellular tyrosine kinasedomain,recruitment of
speciﬁc docking proteins, and activation of intracellular signalingcascades. VEGFR2 heterodimerizes with Ret and induces P of Y1062Ret [1].
Angiotensin (Ang) II, acting via the AT1 receptor (AT1R), transactivates EGFR and Y1062Ret and stimulates their downstream signaling via
the PI3K/Akt and Erk1/2 pathways to induce UB branching [2, 3]. In context of UB morphogenesis,induction of Ret activity is mediated by
Ang II-induced downregulation of Spry1, a physiological inhibitor of RTK signaling[4, 5]. Please see text for details.
Table 1: Receptor tyrosine kinases associated with aberrant kidney development.
RTK type Renal phenotype References
Ret Renal agenesis [26]
FGFR2UB−/− Reduced UB branching and nephron number Defects in stromal patterning [27]
FGFR2Mes−/− Supernumerary UBs, duplex ureters, hydroureter renal agenesis [28]
EGFR Hypoplastic renal medulla, dilated collecting ducts reduced ability to concentrate urine [29]
MetUB−/− Reduced UB branching and nephron number [30]
VEGFR2 Stimulates UB branching, nephrogenesis and vasculogenesis [31–33]
PDGFRα Decreased number of mesangialcell defective stromal mesenchyme [34]
PDGFRβ Lack of mesangial cells and pericytes [35]
RTK: receptortyrosinekinase,Ret: rearrangedduringtransfection,FGF: ﬁbroblastgrowthfactor,UB:uretericbud,Mes:mesenchyme,EGF:epidermalgrowth
factor, Met: hepatocyte growth factor receptor, VEGF: vascular endothelial growth factor, PDGF: platelet-derived growth factor.
that regulate Ret. Ret expression and signaling activity is
inhibited by Sprouty (Spry) 1 and induced by paired box 2
(Pax2) or retinoic acid (vitamin A) [4, 52, 53]. There are
2 isoforms of Ret RTK, Ret9, and Ret51. RET9 (1072 AAs)
and Ret51 (1114 AAs) are identical in N-terminal domain
and diverge after residue 1063 in the C-terminal cytoplasmic
domain [54]. Ret activation results in phosphorylation (P)
of key dockingtyrosines (Y) that bind to several intracellular
adaptor proteins such as Src (at Y981), PLCγ (at Y1015),
SHC,Frs2,Irs1and2,ENIGMA,DOKs4,5and6(atY1062),
and Grb2 (at Y1096) [55]. Recruitment of Src to Ret Y981
activates the MAPK pathway, while recruitment of PLCγ
binding to Ret Y1015 induces the PKC pathway [55]. The
Ret Y1062 phosphotyrosine serves as a docking site for Shc
whichrecruitseithertheGrb2-SoscomplexleadingtoMAPK
activation or Grb2-GAB1 to stimulate PI3K/Akt signaling.
Grb2 also binds to PY1096, where it preferentially activates
PI3K/Akt signaling [56]. Recent elegant genetic studies in
mice identiﬁed distinct roles of Ret RTK Y residues and
their corresponding signaling pathways in the pathogenesis
of diverse types of CAKUT [57]. Mutations in Y1015 of
either Ret9 or Ret51 cause supernumerary ureters, renal
hypodysplasia, and hydroureters. Interestingly, mutations in
Y981 or Y1062 of Ret9 cause CAKUT (partial hydroureter4 Journal of Signal Transduction
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Figure 3: Schematic representation of the steps in kidney organogenesis requiring receptor tyrosine kinase signaling. M: mesenchyme, DT:
distal tubule, E: vascular endothelial cells, UB: ureteric bud, CD: collecting duct, Pod: podocytes. Please see text for details.
Table 2: Ligands of receptor tyrosine kinases with demonstrated functions in kidney organogenesis.
Ligand Model Renal phenotype References
EGF IMCD3 cells Induction of cell migration and process formationin vitro [36]
UB cells Induction of branching morphogenesis in vitro [37]
FGF7 FGF7−/− Smallkidneys, reduced UB branching and nephron number [38]
FGF8 Pax3Cre/FGF loxP/loxP Smallkidneys, reduced number of collecting duct tips lack of progression
of nephrogenesis to the S-shaped body stage short tubules [39]
BrachyuryCre/FGF loxP/loxP Smallkidneys, reduced UB branching, lack of progression of nephrogenesis
to the comma- and S-shaped body stages [40]
FGF10 FGF10−/− Smallkidneys, dysplasia of outer medulla [41]
GDNF GDNF−/− Renal agenesis [42]
HGF IMCD3 cells Induction of cell process formation in vitro [36]
IGF1 UB cells Induction of cell process formation in vitro [43]
PDGF-B PDGF-B−/− Lack of mesangial cells and pericytes [44]
VEGF Rat metanephric organ
culture Induction of vasculogenesis and tubulogenesis in vitro [32]
Mouse metanephric organ
culture Induction of UB branching and nephrons [31]
Rat metanephric and
isolated intact UB culture Induction of UB branching [33]
NephrinCre/VEGF-
AloxP/loxP
Smallglomeruli, paucity of glomerular capillary loops eﬀacement of
podocyte foot processes [45]
UB: ureteric bud, IMCD3: murine inner medullary collecting duct cells.
and bilateral renal agenesis, resp.), whereas same mutations
in Ret51 do not lead to CAKUT. Notably, mutations in
Y1015 of Ret51 cause CAKUT alone, but mutations in
Y981 or Y1062 of Ret9 result in CAKUT and Hirschsprung
disease [58]. These ﬁndings indicate that signaling pathways
downstream of Ret RTK have distinct and redundant roles in
kidney development: PLCγ in ensuring only a single kidney
isformed andPI3K/MAPKinpromoting initiation ofkidney
formation. In addition, the ratio of Ret9/Ret51isoforms may
play an important role in the type and severity of CAKUT.
What are the cellular mechanisms by which Ret signaling
regulates UBand metanephric morphogenesis? Activation of
Ret by GDNF induces cell proliferation in the UB tip cells
[59, 60]. Localized cell proliferation may promote expansion
of the UB tip and subsequent transformation of the rounded
ampulla to a branched structure. Another mechanism mayJournal of Signal Transduction 5
involve change in UB tip cell shape. Here, UB branching
occurs through outpouching possibly mediated by wedge-
shaped cells created through an apical cytoskeletal purse-
string mechanism [61]. This possibility is further supported
by the ability of actin depolymerizing factors, coﬁlin1 and
destrin, to promoteUB epithelial cellsgrowth and branching
[62]. Recent in vivo studies demonstrate that movement of
Ret-expressing NDcellsaccountsfor theUBoutgrowthfrom
the ND [49]. Induction of cell movement by Ret RTK is
mediated by ETS transcription factors, Etv4 and Etv5 [63].
Although the mechanisms by which Ret signaling induces
metanephricorganogenesisremaintobefullyelucidated,cell
proliferation, migration, and shape change are a likely pre-
requisite for Ret-mediated UB branching and metanephric
organogenesis.
3.FibroblastGrowthFactorReceptors
Fibroblastgrowth factor receptors(FGFRs) have four known
signaling members and 22 ligands in mammals [64]. FGFRs
are expressed throughout embryogenesis in many tissues,
including the kidney and are critical in the development
of multiple organs [64]. Since FGFR1- and FGFR2-null
mice are early embryonic lethal [65, 66], conditional gene
knockout approaches were utilized to reveal roles for these
RTKs in kidney development. UB-speciﬁc inactivation of
the FGFR2, which mediates signaling induced by FGF7
and FGF10, in mice reduces UB branching and nephron
number [27, 67, 68]. These eﬀects are mediated, in part,
by FGFR2 substrate 2alpha (Frs2alpha), a major docking
protein for FGFR2 [69]. Although c-Ret gene expression is
not altered in FGFR2UB−/− embryonic metanephroi [27], the
full impact of FGFR2 deﬁciency on Ret signaling remains
to be determined. Conditional inactivation of FGFR2 in the
mesenchyme results in supernumerary UBs, duplex ureters,
hydroureter, and renal agenesis [28]. Notably, mutations of
FGFR2 in humans cause hydroureter and solitary kidney
[70]. Interestingly, UB branching may be induced in vitro
independently of Ret by the addition of FGF7 along with
a c t i v i nA ,a na c t i v a t o ro fT G F - β signaling, or of FGF10 [49,
71].Notably,FGF10becomescriticalforUBbranching when
Ret signaling is reduced or absent. In this regard, reduc-
tion in FGF10 gene dosage in double-transgenic GDNF−/−
/Spry1−/− mice results in renal agenesis [72]. GDNF−/−
or Ret−/− mice exhibit bilateral kidney agenesis [26, 42],
whereas Spry1−/− mice develop supernumerary UB buds
from the ND which subsequently develop into multiple
ureters and kidneys [4]. Interestingly, double-transgenic
GDNF−/−/Spry1−/− or Ret−/−/Spry1−/− mice form normal
ureters and kidneys [72]. These ﬁndings indicate that in
the absence of Spry1, a negative regulator of Ret signaling,
Ret is no longer required for proper kidney development.
Collectively,theseobservationssuggestthat whenGDNFand
Spry1 are both absent, FGF10/FGFR2 signaling allows UB
branching and kidney development. Despite considerable
similarities, renal phenotypes are not identical in FGF7- or
FGF10-null compared to FGFR2UB−/− mice. For example,
UB branching defect is more severe in FGFR2UB−/− than
FGF7- or FGF10-null metanephroi [27, 38, 41]. In addition,
FGFR2UB−/− metanephroi exhibit defects instromal pattern-
ing,aphenotypewhichwasnotreportedinFGF7-orFGF10-
null mice[27,38,41].Thephenotypicdiﬀerencesmaybedue
to diﬀerences in background strains and therefore modiﬁer
genes. Another possibility is that collaborative eﬀect of FGF7
and FGF10 (or FGFR2 ligands other than FGF7/FGF10) may
be required for kidney morphogenesis.
FGFRs activate several signaling pathways common to
Ret [73]. For example, treatment of kidneys with exogenous
FGF10, but not FGF7, induces Etv4/Etv5 expression [74].
Induction of Etv4/Etv5 in the UB is abrogated by inhibition
of PI3K pathway (activated by both Ret and FGFRs) [74].
Since Etv4/Etv5 expression is not altered in FGFR2-null
kidneys, they may be regulated primarily by Ret, but not
FGFR2, signaling. However, the ability of Etv4−/−/Etv5−/−
ND cells to contribute to the UB in chimeric mouse kidneys
is severely compromised compared with Ret−/− cells [63].
These observations suggest that Etv4/Etv5 not only function
downstream of Ret in kidney development, but also have a
broader role downstream of multiple RTKs.
4.EpidermalGrowthFactorReceptor
Signaling through epidermal growth factor receptor (EGFR)
is critical for fundamental cellular functions such as
proliferation, migration, growth, and diﬀerentiation [75].
In addition to EGF, EGF-like growth factors (HB-EGF,
amphiregulin, betacellulin, epigen, and epiregulin) bind to
EGFR [76]. During metanephric development, EGFR is
expressed in renal collecting ducts [29, 77]. Stimulation
of EGFR with EGF enhances branching morphogenesis in
murine inner medullary collecting duct (IMCD3) cells in
vitro [36, 37]. Moreover, EGFR-mutant mice die within 1
week of postnatal life and exhibit abnormal collecting ducts
[78]. Targeted inactivation of the EGFR in mice results
in hypoplastic renal medulla, dilated collecting ducts, and
reduced ability to concentrate urine [29]. These changes are
accompanied by increased apoptosis of papillary epithelia.
Collectively, these ﬁndings indicate that FGFR is essential for
collecting duct growth/elongation and maturation of renal
urine-concentrating ability. The signaling events linking
EGFRactivationandUB/collectingductmorphogenesis may
include MAP kinase and PI3K pathways. In this regard,
pharmacologic inhibition of Erk1/2 or PI3K attenuates EGF-
induced renal epithelial morphogenesis in vitro [36].
5.Met
In the developing metanephros, hepatocyte growth factor
(HGF) is expressed in the mesenchyme, whereas Met is
localized in the mesenchyme and the UB [79]. Genetic
inactivation of HGF or Met in mice results in early embry-
onic lethality due to liver and placental anomalies [80].
Targeted inactivation of Met in the UB causes decreased UB
branching and reduced nephron number [30]. Interestingly,
EGFR expression is induced in kidneys of Met−/− compared
with wild-type mice. This is accompanied by increased6 Journal of Signal Transduction
phosphorylation of Y992 and Y1068 of EGFR. Moreover,
defects in UB branching and nephron number are more
severe in double-mutant mice that lack both Met and
EGFR compared with Met−/− mice [30]. These ﬁndings
indicate that Met and EGFR play complementary roles in
collecting duct growth and nephrogenesis. In addition, Met
and α3β1 integrin, a major laminin receptor essential for
kidney development, signal coordinately to regulate the
expression of Wnt7b which acts to promote normal renal
papillary development [81]. Met signals via Erk1/2, PI3K,
Pkc, Plc, Src, Fac, and Jak/Stat [82–85]. With respect to
kidney development, activation of Erk1/2, PI3K, and PLCγ
signaling pathways is critical for HGF-induced cell motility
and branching process formation in IMCD-3 cells in vitro
[36].
6.VascularEndothelialGrowth
FactorReceptor2
Vascular endothelial growth factor (VEGF) acts viaVEGFR1
(Flt1) and VEGFR2 (KDR) to regulate endothelial cell pro-
liferation, migration, and diﬀerentiation [86]. Most actions
of VEGF are mediated via VEGFR2, whereas VEGFR1
is considered a “decoy” RTK. In the adult rat kidney,
VEGFR2 is present in glomerular endothelial, distal tubule
and collecting duct cells [87]. VEGF mRNA is expressed
in both the UB and the mesenchyme in the developing
mouse metanephros [31]. It is believed that VEGF released
by the podocytes induces migration of vascular endothelial
cells into the vascular cleft [32]. In turn, endothelial
cells promote diﬀerentiation of renal mesangial cells via
production of platelet-derived growth factor (PDGF) [88].
Exogenous VEGF stimulates nephrogenesis, UB branching
and vasculogenesis [31, 32]. Notably, the eﬀect of VEGF on
UB morphogenesis is mediated viaVEGFR2 [33]. Moreover,
VEGFR2 physically interacts with Ret, and exogenous VEGF
induces phosphorylation of Y1062 in Ret in UB-derived
cells in vitro [1]. These ﬁndings suggest that cooperation
of VEGFR2 and Ret may play an important role in renal
collecting system development.
7.Platelet-DerivedGrowthFactorReceptors
Two PDGF receptors, PDGFRα and PDGFRβ,m e d i a t et h e
eﬀect of ﬁve PDGFs each functioning in dimeric conﬁgu-
rations AA, BB, AB, CC, and DD [23, 89]. In the human
fetal kidney, PDGF-C localized to the mesangium, UB and
the mesenchyme [90]. In the adult kidney, PDGF-C is
expressed in parietal epithelial cells of Bowman’s capsule,
loops of Henle, distal tubules, collecting ducts and in arterial
endothelial cells [90]. Genetic inactivation of the PDGFRβ
in mice results in lack of mesangial cells and pericytes of the
glomerular capillaries [35]. Conditional inactivation of the
PDGFRβ in mice causes podocyte hypertrophy, glomerular
capillary collapse, and preventsage-related mesangial expan-
sion [91]. PDGFRα-null mice also exhibit decreased mesan-
gialcellrecruitment anddefectivestromal mesenchyme [34].
Therefore, one role of PDGF released by the glomerular
endothelial cells during metanephrogenesis is to promote
diﬀerentiation of mesangial cells and promote glomerular
vasculogenesis [88].
8.Insulin GrowthFactorReceptors
The insulin-like growth factor (IGF) family includes ligands
(IGF1, IGF2, and insulin) and their respective receptors
(IGF1R, IGF2R, and InsR). IGFs/IGFRs play an essential role
in the regulation of cell growth, proliferation, survival and
aﬀect function of many organ systems. In the adult canine
kidney, both IGF1R and IGF2R are detected in the proximal
tubular cells by binding autoradiography [92]. IGF1R,
IGF2R and insulin receptor (INSR) mRNA and protein
are expressed ubiquitously in the developing metanephros
as early as on embryonic (E) day 14.0 in the rat [93].
At later stages of gestation, IGF1R expression is enhanced
in the proximal tubules. IGF1/2 mRNA is also present in
the rat kidney from E13.0 and treatment of metanephroi
with anti-IGF1/2 antibodies retards kidney growth ex vivo
[94]. Interestingly, intrauterine growth restriction (IUGR)
in rats is accompanied by a decreased glomerular number
and reduced IGF2R protein expression [95]. In contrast,
fetal kidney IGF1 and insulin protein levels are increased
compared with nonmanipulated embryos. Therefore, IGFRs
promotenephrogenesis and renal organogenesis, and may be
causally linked to occurrence of renal hypodysplasia.
9.Renin-Angiotensin System-RTK Crosstalk in
KidneyDevelopment
Crosstalk with RTKs has been shown to mediate the growth
factor-like eﬀects of a number of G protein-coupled receptor
(GPCR-) activating ligands, such as angiotensin (Ang) II.
We recently examined the role of Ret and EGFR in Ang
II-induced UB branching. The critical role of the renin-
angiotensin system (RAS) in metanephric development is
evident from the observations that genetic inactivation of
its components, such as angiotensinogen (AGT), renin,
angiotensin-converting enzyme (ACE), or Ang II receptors
(AT1R, AT2R) in mice causes hydronephrosis, hypoplastic
medulla, and papilla [96]. AT2R-mutant mice demonstrate
increased incidence of duplex ureters and vesicoureteral
reﬂux [97]. Mutations in the genes encoding for AGT,
renin, ACE or AT1R in humans are associated with renal
tubular dysgenesis (RTD) [98]. In RTD, collapsed collecting
ducts and abundant interstitial ﬁbrosis in the medulla
are observed. Given that EGFR- and Y1062Ret-mutant mice
exhibit CAKUT, we recently examined the role of EGFR and
Y1062Ret in Ang-II-induced UB branching morphogenesis.
Ang-II increases phosphorylation of Y1173 and Y845 of
EGFR in UB-derived cells in vitro and of Y1062Ret in whole
embryonic metanephroi grown ex vivo [2, 3]. Notably,
Y1173 and Y845 of EGFR are the major sites of EGFR
autophosphorylationwhichoccursasaresultofEGFbinding
[98]. Moreover, inhibition of EGFR activity with the speciﬁc
antagonist AG1478 abrogates Ang-II-induced UB branching
in the intact metanephros [2]. Since, Y1062R e ts e r v e sa saJournal of Signal Transduction 7
docking site for protein complexes that activate PI3K/Akt
and Erk1/2 signaling pathways [57, 99], we recently exam-
ined the ability of Ang II to induce phosphorylation of Akt.
Treatment of whole intact E12.5 metanephroi or UB cells
with Ang II increases phosphorylation of Akt [3]. Moreover,
Ang-II-induced increase in UB branching is abrogated by
pretreatment with the speciﬁc PI3K inhibitor LY294002 or
Erk1/2 inhibitor PD98059 [3]. These ﬁndings indicate that
PI3K/Akt and Erk1/2 are essential for Ang-II-induced UB
branching. Since exogenous Ang II decreases the expression
of Spry1 in whole embryonic mouse metanephroi and in UB
cells cultured in vitro,t h es t i m u l a t o r ye ﬀects of Ang II on
EGFR and Ret Y phosphorylation and UB branching may
be mediated via downregulation of Spry1, a physiological
inhibitor of RTK signaling [5]. Collectively, our data indicate
that stimulation of Ang II GPCRs by their ligand induces
tyrosine phosphorylation of EGFR and Ret leading to
enhancedUBmorphogeneticsignaling andbranching.Thus,
cooperation of Ang II receptor and EGFR/Ret signaling is
important in the developmentof the renal collecting sustem.
10.Conclusionsand Perspectives
RTKs are emerging as critical players in normal metanephric
kidney development.It has become evident that not only the
classical direct stimulation of RTKs by their cognate ligands,
but also ligand-independent, through transactivation of
RTKsby G protein-coupled receptors, or heterodimerization
with other RTKs play an important role in UB branching
and metanephric organogenesis. Even though signiﬁcant
progress have been made in deﬁning the role of RTKs and
speciﬁc contribution of RTK-dependent signal transduction
in metanephric development, further characterization of
the subcellular processes involved in RTK activation and
signaling is needed.
What are the major open questions regarding RTK
signaling during kidney organogenesis? These include eluci-
dation of how activation of RTK signaling aﬀects the phos-
phoproteome in the developing kidney and the cell type-
speciﬁc responses to signals transmitted by distinct signaling
pathways activated by RTKs. What are the perspectives for
systems-wide approaches to understand RTK signaling in
kidney organogenesis? In this regard, application of new
genetic tools, such as conditional/tissue/cell-speciﬁc gene
knockouts, genetic lineage tracing, and ﬂuorescent in vivo
reporters of cell signaling, whole genome-wide analysis of
gene regulatory networks (including epigenetic regulation)
that control diﬀerent aspects of kidney development (e.g.,
microarray, ChIP-Seq) should provide important insights
in understanding molecular mechanisms that direct normal
and abnormal metanephric kidney development. Deﬁning
molecular aberrations leading to CAKUT in animals and
humans with mutations in genes encoding for RTKs and
their cognate ligands will uncover biomarkers that can
be used for early diagnosis or prevention of renal system
anomalies in children. Finally, establishment of shared large
biorepositories of patients encompassing a wide spectrum of
CAKUTphenotypesformolecular, genetic,and translational
studieswilldeﬁneclinicallyrelevantmutationsinRTKs,their
ligands, and interacting genes. This information can then
be used to develop new eﬀective preventive or therapeutic
interventions for CAKUT.
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